1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

EMA Is Exploring How Real-World Data Can Benefit Europe’s OTC Market, Says Agency Head Rasi

 
• By David Ridley

The European Medicines Agency is right now looking into how real-world data and evidence can be used to improve regulatory systems and extend access to OTC medicines within the European Union, the agency's executive director Guido Rasi told the recent AESGP Regulatory Conference in Amsterdam.

Real world data
Real-world data can be used to expand access to OTCs • Source: Shutterstock

“Real-world data” (RWD) and “real-world evidence” (RWE) are fast becoming buzzwords in the global consumer healthcare industry, often mentioned with excitement within discussions about the future of the global OTC market.

For firms, RWD generated through smartphone apps and wearables offers a cost-efficient way to supplement the expensive clinical evidence needed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 
• By Sarah Karlin-Smith

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

Manufacturers Can Keep Their Shoes On: FDA PreCheck To Streamline US Facility Applications

 
• By Derrick Gingery

The program would allow early interactions with FDA staff to speed construction and approval of pharmaceutical manufacturing facilities in the US, but will staff be available?

NDA User Fees Increasing 8.6% As FDA Projects More Applications But Fewer Sponsor Meetings

 
• By Nielsen Hobbs and Derrick Gingery

The ups – and some downs – of the US FDA’s prescription, biosimilar, and generic user fees for FY 2026 are tabulated by the Pink Sheet.

More from Policy & Regulation

Inspection Readiness 101: Prepare To Avoid Common Pitfalls When The FDA Comes Knocking

 
• By Brian Bossetta

A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 
• By Sarah Karlin-Smith

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

Industry Pleased To See Self-Care In Revised English Children’s Education Policy

 
• By David Ridley

Children and young adults will in future learn more about responsible self-care, including when it is appropriate to see a pharmacist, specific instructions for dental health and information about health risks associated with smoking, vaping, and other nicotine products such as nicotine pouches.